Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 12 or older who weigh at least 40 kg (about 88 pounds)
• People whose general health and ability to carry out daily activities meets a certain minimum level (confirm with trial site)
• People who have acute leukemia (of myeloid, lymphoid, or mixed type) that has come back or stopped responding to treatment, and whose leukemia has specific genetic changes linked to a group of genes called HOX genes — the exact genetic changes considered eligible are listed in the trial criteria (confirm with trial site)
• People whose white blood cell count is below 25,000 per microlitre at the time of joining — treatment to lower the count beforehand may be allowed
• People whose heart is pumping at least 40% of its normal capacity
• People whose liver is functioning at an adequate level, based on specific blood test results (confirm with trial site)
• People whose kidneys are functioning at an adequate level, based on a kidney filtration rate of at least 60 mL/min
• People (or their parent or guardian, if applicable) who are willing and able to give informed consent to participate
• People who have waited an appropriate amount of time since their last treatment before starting the trial — generally at least 14 days or five half-lives of the prior treatment, with some exceptions allowed for rapidly progressing disease
• People who are able and willing to use adequate contraception during the trial and for at least 3 months after the last treatment

Who may not be able to join:

• People who have another serious uncontrolled medical condition, significant abnormal test results, or a mental health condition that would make participation too risky
• People who are receiving other chemotherapy or anti-leukaemia treatments at the same time — though some limited exceptions apply, such as certain treatments for leukemia affecting the brain and spinal fluid, or short-term treatments for rapidly growing disease (confirm with trial site)
• People who have a severe gut or metabolic condition that could prevent the oral study medication from being properly absorbed
• People who have another active cancer that is currently being treated
• People with a known active hepatitis B, hepatitis C, or HIV infection
• People who are pregnant or breastfeeding
• People who have an active, uncontrolled infection at the time of joining
• People who have had a heart attack, unstable chest pain, significant heart failure, life-threatening irregular heartbeat, stroke, or mini-stroke within the 6 months before joining the trial
• People whose heart's electrical activity (measured by an ECG) shows a reading above a certain threshold — above 450 milliseconds for males and above 470 milliseconds for females
• People who have a history or current condition that, in the investigator's judgement, could affect the trial results, interfere with full participation, or would not be in the person's best interest
• People who have leukemia that is currently active in the brain or spinal fluid
• People who have had a stem cell transplant and are still taking immune-suppressing medications — a minimum waiting period off these medications is required before joining (confirm with trial site)
• People who have moderate to severe graft-versus-host disease (a complication that can occur after a stem cell transplant) that is not well controlled

Important: Always verify eligibility with the trial site directly before applying.